EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cadence Pharmaceuticals,'s enterprise value is €887.38 Mil.
Cadence Pharmaceuticals,'s Revenue for the trailing twelve months (TTM) ended in Dec. 2013 was €84.37 Mil. Therefore, Cadence Pharmaceuticals,'s EV-to-Revenue for today is 10.52.
The historical rank and industry rank for Cadence Pharmaceuticals,'s EV-to-Revenue or its related term are showing as below:
FRA:QEW's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.69 * Ranked among companies with meaningful EV-to-Revenue only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cadence Pharmaceuticals,'s EV-to-Revenue
For the Biotechnology subindustry, Cadence Pharmaceuticals,'s EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cadence Pharmaceuticals,'s EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cadence Pharmaceuticals,'s EV-to-Revenue falls into.
Cadence Pharmaceuticals,'s current Enterprise Value is €887.38 Mil.
Cadence Pharmaceuticals,'s Revenue for the trailing twelve months (TTM) ended in Dec. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €84.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cadence Pharmaceuticals,'s share price for today is €9.95.
Cadence Pharmaceuticals,'s Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.98.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cadence Pharmaceuticals, EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Cadence Pharmaceuticals, (FRA:QEW) Business Description
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:QEW has been successfully added to your 